Brandon F Keele

List of Publications by Year
in descending order

97 papers	11,870 citations	61857 43 h-index	33814 99 g-index
101 all docs	101 docs citations	101 times ranked	8875 citing authors

#	Article	IF	Citations
1	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7552-7557.	3.3	1,708
2	Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1. Science, 2006, 313, 523-526.	6.0	723
3	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. Journal of Experimental Medicine, 2009, 206, 1273-1289.	4.2	684
4	The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. Journal of Experimental Medicine, 2009, 206, 1253-1272.	4.2	562
5	Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. Journal of Virology, 2008, 82, 12449-12463.	1.5	548
6	Immune clearance of highly pathogenic SIV infection. Nature, 2013, 502, 100-104.	13.7	548
7	Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing. Journal of Virology, 2008, 82, 3952-3970.	1.5	540
8	Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature, 2014, 511, 601-605.	13.7	422
9	Quantitating the Multiplicity of Infection with Human Immunodeficiency Virus Type 1 Subtype C Reveals a Non-Poisson Distribution of Transmitted Variants. Journal of Virology, 2009, 83, 3556-3567.	1.5	354
10	Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics. Journal of Experimental Medicine, 2017, 214, 959-972.	4.2	327
11	Clonally expanded CD4 ⁺ T cells can produce infectious HIV-1 in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1883-1888.	3.3	302
12	Inflammatory Genital Infections Mitigate a Severe Genetic Bottleneck in Heterosexual Transmission of Subtype A and C HIV-1. PLoS Pathogens, 2009, 5, e1000274.	2.1	298
13	Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. Journal of Experimental Medicine, 2009, 206, 1117-1134.	4.2	295
14	Generation of Transmitted/Founder HIV-1 Infectious Molecular Clones and Characterization of Their Replication Capacity in CD4 T Lymphocytes and Monocyte-Derived Macrophages. Journal of Virology, 2012, 86, 2715-2728.	1.5	291
15	High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathogens, 2010, 6, e1000890.	2.1	263
16	Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1126-34.	3.3	252
17	Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir. PLoS Pathogens, 2017, 13, e1006283.	2.1	209
18	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nature Medicine, 2016, 22, 762-770.	15.2	197

#	Article	IF	Citations
19	Envelope residue 375 substitutions in simianâ€“human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3413-22.	3.3	170
20	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature, 2014, 505, 502-508.	13.7	140
21	Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIV _{mac251} Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial. Journal of Virology, 2013, 87, 1708-1719.	1.5	130
22	Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy. Journal of Virology, 2016, 90, 1369-1376.	1.5	121
23	Low-Dose Mucosal Simian Immunodeficiency Virus Infection Restricts Early Replication Kinetics and Transmitted Virus Variants in Rhesus Monkeys. Journal of Virology, 2010, 84, 10406-10412.	1.5	120
24	Quality and quantity of T _{FH} cells are critical for broad antibody development in SHIV _{AD8} infection. Science Translational Medicine, 2015, 7, 298ra120.	5.8	119
25	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science Translational Medicine, 2017, 9, .	5.8	87
26	HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus. Journal of Clinical Investigation, 2020, 130, 5847-5857.	3.9	85
27	HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy. Journal of Clinical Investigation, 2019, 129, 4629-4642.	3.9	84
28	Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nature Communications, 2018, 9, 1928.	5.8	83
29	Functional Cure of SIVagm Infection in Rhesus Macaques Results in Complete Recovery of CD4+ T Cells and Is Reverted by CD8+ Cell Depletion. PLoS Pathogens, 2011, 7, e1002170.	2.1	82
30	Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques. AIDS Research and Human Retroviruses, 2016, 32, 163-168.	0.5	79
31	Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25891-25899.	3.3	78
32	Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization. Nature Communications, 2015, 6, 6565.	5.8	77
33	Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy. PLoS Pathogens, 2017, 13, e1006359.	2.1	77
34	HIV-1â€“induced AIDS in monkeys. Science, 2014, 344, 1401-1405.	6.0	76
35	Barriers to mucosal transmission of immunodeficiency viruses. Blood, 2011, 118, 839-846.	0.6	72
36	Comparative Characterization of Transfection- and Infection-Derived Simian Immunodeficiency Virus Challenge Stocks for In Vivo Nonhuman Primate Studies. Journal of Virology, 2013, 87, 4584-4595.	1.5	71

#	Article	IF	Citations
37	DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2975-2980.	3.3	71
38	Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology, 2013, 436, 33-48.	1.1	58
39	Experimental colitis in SIV-uninfected rhesus macaques recapitulates important features of pathogenic SIV infection. Nature Communications, 2015, 6, 8020.	5.8	58
40	Genetic and antigenic features of the transmitted virus. Current Opinion in HIV and AIDS, 2009, 4, 352-357.	1.5	53
41	Protection Afforded by an HIV Vaccine Candidate in Macaques Depends on the Dose of SIV_{mac251}at Challenge Exposure. Journal of Virology, 2013, 87, 3538-3548.	1.5	52
42	Tracking the Luminal Exposure and Lymphatic Drainage Pathways of Intravaginal and Intrarectal Inocula Used in Nonhuman Primate Models of HIV Transmission. PLoS ONE, 2014, 9, e92830.	1.1	50
43	Pathogenicity and Mucosal Transmissibility of the R5-Tropic Simian/Human Immunodeficiency Virus SHIV _{AD8} in Rhesus Macaques: Implications for Use in Vaccine Studies. Journal of Virology, 2012, 86, 8516-8526.	1.5	47
44	Selection of Unadapted, Pathogenic SHIVs Encoding Newly Transmitted HIV-1 Envelope Proteins. Cell Host and Microbe, 2014, 16, 412-418.	5.1	47
45	Molecularly Tagged Simian Immunodeficiency Virus SIVmac239 Synthetic Swarm for Tracking Independent Infection Events. Journal of Virology, 2014, 88, 8077-8090.	1.5	46
46	Intestinal damage precedes mucosal immune dysfunction in SIV infection. Mucosal Immunology, 2018, 11, 1429-1440.	2.7	46
47	HIV Infected T Cells Can Proliferate in vivo Without Inducing Expression of the Integrated Provirus. Frontiers in Microbiology, 2019, 10, 2204.	1.5	46
48	Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. Science Translational Medicine, 2017, 9, .	5.8	45
49	Effect of Suberoylanilide Hydroxamic Acid (SAHA) Administration on the Residual Virus Pool in a Model of Combination Antiretroviral Therapy-Mediated Suppression in SIVmac239-Infected Indian Rhesus Macaques. Antimicrobial Agents and Chemotherapy, 2014, 58, 6790-6806.	1.4	43
50	Identifying and characterizing recently transmitted viruses. Current Opinion in HIV and AIDS, 2010, 5, 327-334.	1.5	41
51	Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies. Current Opinion in HIV and AIDS, 2016, 11, 546-554.	1.5	40
52	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. Journal of Virology, 2017, 91, .	1.5	40
53	Comparison of systemic and mucosal vaccination: impact on intravenous and rectal SIV challenge. Mucosal Immunology, 2012, 5, 41-52.	2.7	39
54	Control of Heterologous Simian Immunodeficiency Virus SIV _{smE660} Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. Journal of Virology, 2018, 92, .	1.5	39

#	Article	IF	Citations
55	Antibody to the gp120 V1/V2 Loops and CD4+ and CD8+ T Cell Responses in Protection from SIVmac251 Vaginal Acquisition and Persistent Viremia. Journal of Immunology, 2014, 193, 6172-6183.	0.4	34
56	Using nonhuman primates to model HIV transmission. Current Opinion in HIV and AIDS, 2013, 8, 1.	1.5	31
57	Pathogenic Features Associated with Increased Virulence upon Simian Immunodeficiency Virus Cross-Species Transmission from Natural Hosts. Journal of Virology, 2014, 88, 6778-6792.	1.5	31
58	Blocking Î± ₄ Î² ₇ integrin binding to SIV does not improve virologic control. Science, 2019, 365, 1033-1036.	6.0	31
59	Lack of therapeutic efficacy of an antibody to Î± ₄ Î² ₇ in SIVmac251-infected rhesus macaques. Science, 2019, 365, 1029-1033.	6.0	31
60	Defining early SIV replication and dissemination dynamics following vaginal transmission. Science Advances, 2019, 5, eaav7116.	4.7	30
61	Elevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy. Antimicrobial Agents and Chemotherapy, 2016, 60, 1560-1572.	1.4	29
62	Evaluation of an antibody to Î± ₄ Î² ₇ in the control of SIVmac239- nef-stop infection. Science, 2019, 365, 1025-1029.	6.0	29
63	A single gp120 residue can affect HIV-1 tropism in macaques. PLoS Pathogens, 2017, 13, e1006572.	2.1	28
64	Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. JCI Insight, 2019, 4, .	2.3	25
65	A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host. PLoS Pathogens, 2017, 13, e1006358.	2.1	25
66	In Vivo Validation of the Viral Barcoding of Simian Immunodeficiency Virus SIVmac239 and the Development of New Barcoded SIV and Subtype B and C Simian-Human Immunodeficiency Viruses. Journal of Virology, 2019, 94, .	1.5	24
67	Evaluating the Intactness of Persistent Viral Genomes in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Initiating Antiretroviral Therapy within One Year of Infection. Journal of Virology, 2019, 94, .	1.5	23
68	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention, and Cure. Journal of Virology, 2021, 95, .	1.5	21
69	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. PLoS Pathogens, 2019, 15, e1007632.	2.1	20
70	Derivation and Characterization of Pathogenic Transmitted/Founder Molecular Clones from Simian Immunodeficiency Virus SIVsmE660 and SIVmac251 following Mucosal Infection. Journal of Virology, 2016, 90, 8435-8453.	1.5	19
71	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys. Cell Reports, 2022, 38, 110199.	2.9	19
72	A Vaccine against CCR5 Protects a Subset of Macaques upon Intravaginal Challenge with Simian Immunodeficiency Virus SIVmac251. Journal of Virology, 2014, 88, 2011-2024.	1.5	18

#	Article	IF	Citations
73	CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification. Journal of Clinical Investigation, 2021, 131, .	3.9	18
74	Predictors of SIV recrudescence following antiretroviral treatment interruption. ELife, 2019, 8, .	2.8	18
75	Restricted Replication of Xenotropic Murine Leukemia Virus-Related Virus in Pigtailed Macaques. Journal of Virology, 2012, 86, 3152-3166.	1.5	16
76	Adoptive Transfer of Engineered Rhesus Simian Immunodeficiency Virus-Specific CD8⁺T Cells Reduces the Number of Transmitted/Founder Viruses Established in Rhesus Macaques. Journal of Virology, 2016, 90, 9942-9952.	1.5	14
77	Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10504-10509.	3.3	14
78	Marginal Effects of Systemic CCR5 Blockade with Maraviroc on Oral Simian Immunodeficiency Virus Transmission to Infant Macaques. Journal of Virology, 2018, 92, .	1.5	13
79	Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency. Journal of Virology, 2018, 92, .	1.5	12
80	Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. Nature Communications, 2017, 8, 15740.	5.8	11
81	Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes. Journal of Virology, 2019, 93, .	1.5	11
82	Antibody-mediated depletion of viral reservoirs is limited in SIV-infected macaques treated early with antiretroviral therapy. Journal of Clinical Investigation, 2021, 131, .	3.9	11
83	Blocking Î± ₄ Î² ₇ integrin delays viral rebound in SHIV _{SF162P3} -infected macaques treated with anti-HIV broadly neutralizing antibodies. Science Translational Medicine, 2021, 13, .	5.8	11
84	Mitigation of endemic GI-tract pathogen-mediated inflammation through development of multimodal treatment regimen and its impact on SIV acquisition in rhesus macaques. PLoS Pathogens, 2021, 17, e1009565.	2.1	10
85	Genetically barcoded SIV reveals the emergence of escape mutations in multiple viral lineages during immune escape. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 494-502.	3.3	9
86	Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation. Nature Communications, 2020, 11, 5412.	5.8	9
87	Transcription Start Site Heterogeneity and Preferential Packaging of Specific Full-Length RNA Species Are Conserved Features of Primate Lentiviruses. Microbiology Spectrum, 2022, 10, .	1.2	8
88	Ultrasensitive Immunoassay for Simian Immunodeficiency Virus p27^{CA}. AIDS Research and Human Retroviruses, 2018, 34, 993-1001.	0.5	7
89	Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice. Journal of Virology, 2020, 94, .	1.5	7
90	Transient viral replication during analytical treatment interruptions in SIV infected macaques can alter the rebound-competent viral reservoir. PLoS Pathogens, 2021, 17, e1009686.	2.1	7

#	Article	IF	Citations
91	Generation and characterization of a SIVmac239 clone corrected at four suboptimal nucleotides. Retrovirology, 2015, 12, 49.	0.9	6
92	CpG Methylation Profiles of HIV-1 Proviral DNA in Individuals on ART. Viruses, 2021, 13, 799.	1.5	6
93	Low-level alternative tRNA priming of reverse transcription of HIV-1 and SIV in vivo. Retrovirology, 2019, 16, 11.	0.9	3
94	Insertion as a Resistance Mechanism Against Integrase Inhibitors in Several Retroviruses. Clinical Infectious Diseases, 2019, 69, 1460-1461.	2.9	2
95	Lack of Specific Regulatory T Cell Depletion and Cytoreduction Associated with Extensive Toxicity After Administration of Low and High Doses of Cyclophosphamide. AIDS Research and Human Retroviruses, 2022, 38, 45-49.	0.5	1
96	Impact of fluctuation in frequency of human immunodeficiency virus/simian immunodeficiency virus reactivation during antiretroviral therapy interruption. Proceedings of the Royal Society B: Biological Sciences, 2020, 287, 20200354.	1.2	1
97	The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth. PLoS ONE, 2021, 16, e0260010.	1.1	1